Shanghai RAAS Blood Products Co., Ltd.
002252
Rank in Stocks
#3569
Shanghai RAAS Blood Products Co., Ltd. engages in the research, development,... Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnostic reagents, and testing services. The company was founded by Kieu Hoang on October 29, 1988 and is headquartered in Shanghai, China.
Share Price
$0.72625991
Market Cap
$4.79B
Change (1 day)
2.70%
Change (1 year)
-22.68%
Country
CN
Trade Shanghai RAAS Blood Products Co., Ltd. (002252)
Category
Healthcare
Revenue for Shanghai RAAS Blood Products Co., Ltd. (002252)
Revenue in Jun 2026 TTM: $957.22M
According to Shanghai RAAS Blood Products Co., Ltd. latest financial reports the company's current revenue (TTM) is $957.22M. In 2023 the company made a revenue of $1.13B an increase over the revenue in the year 2022 that was $952.06M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Shanghai RAAS Blood Products Co., Ltd. from 2005 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $957.22M | -14.55% |
| 2024 | $1.12B | -0.43% |
| 2023 | $1.13B | 18.17% |
| 2022 | $952.06M | 41.13% |
| 2021 | $674.61M | 59.58% |
| 2020 | $422.75M | 13.88% |
| 2019 | $371.23M | 41.53% |
| 2018 | $262.30M | -11.47% |
| 2017 | $296.29M | -11.57% |
| 2016 | $335.05M | 8.07% |
| 2015 | $310.04M | 45.51% |
| 2014 | $213.07M | 160.38% |
| 2013 | $81.83M | -23.00% |
| 2012 | $106.27M | 19.77% |
| 2011 | $88.73M | 21.16% |
| 2010 | $73.23M | 29.02% |
| 2009 | $56.76M | 25.00% |
| 2008 | $45.41M | 6.97% |
| 2007 | $42.45M | 18.91% |
| 2006 | $35.70M | -4.95% |
| 2005 | $37.56M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 1,218.84% |
US
|
|
| $2.23B | 132.76% |
US
|
|
| $15.74B | 1,544.79% |
AU
|
|
| $6.02B | 529.04% |
NL
|
|
| - | - |
CH
|
